Genes & biomarkers

FGFR3 variants

FGFR3 · urothelial cancer

Relevant to treatment in some advanced urothelial cancers.

Sources checked · Introductory guide

On this page

What does this result mean?

FGFR3 encodes a growth-signaling receptor. Alterations occur in some urothelial cancers, including bladder cancer. Despite similar names, FGFR2 and FGFR3 are separate genes.[1]

How does it connect to treatment?

Erdafitinib is used in selected advanced FGFR3-altered urothelial cancers after progression on systemic therapy. FGFR2 criteria from bile duct cancer do not directly apply.[2]

What should I check in my report?

Confirm the precise qualifying FGFR3 alteration. If treatment is considered, ask about required follow-up, including eye checks and phosphate measurements.

Questions for your care team

  • Do my FGFR3 result and prior treatment meet the drug criteria?
  • Which treatments or trials fit my cancer type, stage and previous treatment?

Sources and scope

Source documents are in English.

Entries summarize and translate linked official public sources. The source-check date records when those sources were checked; it does not indicate a clinician’s review.

  1. MedlinePlus Genetics · FGFR3 (opens in a new tab)
  2. NCI · erdafitinib (opens in a new tab)

General information based on official public sources. This is not a complete list of uses or side effects. Individual treatment decisions require your care team and current source documents. US-source uses do not establish local approval or reimbursement.

Related entries

FGFR3 variants | Cancer Encyclopedia | My Chemo Diary